All News

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights to commercialize the treatment outside of North America.

Valencia will seek to leverage the investment as well as Surek’s leadership experience to drive commercialization of its flagship eCoin system to develop minimally invasive treatments for urinary incontinence.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about how collaborations, like the one with Celltrion, have been instrumental in the company's success.

Led by Bosch Ventures, Applyo Jena’s Series A funding seeks to accelerate the development and commercialization of its advanced pharmaceutical technologies.

Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens through Epitopea’s CryptoMap platform.

Former leaders of the CDC, FDA, and other agencies condemned the layoffs.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about how the recent NASDAQ listing will aid in accelerating R&D and commercialization efforts.

Vimkunya is the first FDA-approved vaccine for chikungunya in patients over 12 years of age.

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro gives an update on the preclinical development of Abpro's lead HER2/CD3 T cell engager.

Meilog marks the first rapid-acting insulin biosimilar to gain FDA approval for the treatment of diabetes.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about the challenges faced in developing T cell engagers.

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial intelligence in the drug discovery process.

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ineligible for autologous stem cell transplantation.

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering.

The latest news for pharma industry insiders.

As part of the funding, Latent Labs aims to leverage generative artificial intelligence to computationally create novel therapeutic molecules, such as antibodies and enzymes, to improve molecular features.

Kennedy was confirmed by a mostly party-line vote in the Senate.

Evrysdi is a non-invasive, disease-modifying option that can be swallowed whole or dispersed in water for patients with spinal muscular atrophy.

The latest news for pharma industry insiders.

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients with atrial fibrillation and cancer-associated thrombosis.

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1, a genetic disorder that causes noncancerous tumors to grow on nerves throughout the body.

PwC report identifies transformative trends impacting the pharma market this year and into the future.